sirna gene silencing shrnas  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Millipore sirna gene silencing shrnas
    Sirna Gene Silencing Shrnas, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sirna gene silencing shrnas/product/Millipore
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sirna gene silencing shrnas - by Bioz Stars, 2020-09
    99/100 stars

    Images

    Related Articles

    Western Blot:

    Article Title: Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression
    Article Snippet: .. Cancer cell lines were transfected with scrambled-siRNA or METTL14-siRNA/ALKBH5-siRNA (Sigma-Aldrich) for 48 or 72 hours before they were subjected to qRT-PCR or Western blot analysis, as described previously ( ). .. Antibodies against ALKBH5 (#HPA 007196), β-actin (#A3854), GAPDH (#G9295), and METTL14 (#HPA038002) were purchased from Sigma-Aldrich.

    Transfection:

    Article Title: MICU1 drives glycolysis and chemoresistance in ovarian cancer
    Article Snippet: .. Plasmids and siRNA transfection Gene silencing was performed for CP20 and OV90 cell lines in 6 cm culture dish containing 5 × 105 cells using Hiperfect (Qiagen) and commercially validated 10 μM siRNA (scrambled control siRNA (#1027280), QIAGEN, CA, USA) or siRNA against human MICU1 (SASI_Hs01_00070243, SASI_Hs01_00070249 Sigma) (# S1041403600 Qiagen) in OPTIMEM (Invitrogen). .. Effective silencing was achieved after 48-72 h of transfection (determined by protein expression) and all experiments with gene silencing were performed 48-96 h post transfection.

    Article Title: Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression
    Article Snippet: .. Cancer cell lines were transfected with scrambled-siRNA or METTL14-siRNA/ALKBH5-siRNA (Sigma-Aldrich) for 48 or 72 hours before they were subjected to qRT-PCR or Western blot analysis, as described previously ( ). .. Antibodies against ALKBH5 (#HPA 007196), β-actin (#A3854), GAPDH (#G9295), and METTL14 (#HPA038002) were purchased from Sigma-Aldrich.

    Negative Control:

    Article Title: Combining peptide TNIIIA2 with all-trans retinoic acid accelerates N-Myc protein degradation and neuronal differentiation in MYCN-amplified neuroblastoma cells
    Article Snippet: .. 200 μL of Opti-MEM (Invitrogen) including talin small interference RNA (siRNA) (Sigma) or siPerfect Negative Control (Sigma) and 2 μL of Lipofectamine RNAi Max (Invitrogen) were mixed and placed still for 20 minutes at room temperature. .. 1 mL of IMR-32 cell suspension (6 × 104 cells/mL) was added to the solution and the mixture was incubated in a 5% CO2 incubator at 37°C for 48 hours.

    Quantitative RT-PCR:

    Article Title: Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression
    Article Snippet: .. Cancer cell lines were transfected with scrambled-siRNA or METTL14-siRNA/ALKBH5-siRNA (Sigma-Aldrich) for 48 or 72 hours before they were subjected to qRT-PCR or Western blot analysis, as described previously ( ). .. Antibodies against ALKBH5 (#HPA 007196), β-actin (#A3854), GAPDH (#G9295), and METTL14 (#HPA038002) were purchased from Sigma-Aldrich.

    Lysis:

    Article Title: Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
    Article Snippet: .. Ago2-bound siRNA from mouse liver was quantified by preparing liver lysates at 100 mg/ml in lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2mM EDTA, 0.5% Triton-X 100) supplemented with freshly added protease inhibitors (Sigma-Aldrich, P8340) at 1:100 dilution and 1 mM PMSF (Life Technologies). .. Total liver lysate (10 mg) was used for each Ago2 immunoprecipitation (IP) and control IP.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Millipore sirna gene silencing
    KD of EGR2 Reduces COL1A1 and PDGFRB mRNA Levels in Human <t>HSC</t> Line (A–C) Graphs show the effect of <t>siRNA-KD</t> of the indicated genes (x axis) on relative mRNA levels of EGR2 (A), COL1A1 (B), and PDGFRB (C). The effect of three independent siRNAs against EGR2 is shown. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA and Dunnett’s post test. Statistical differences are indicated as ***p
    Sirna Gene Silencing, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sirna gene silencing/product/Millipore
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sirna gene silencing - by Bioz Stars, 2020-09
    99/100 stars
      Buy from Supplier

    99
    Millipore inducible gene silencing muc1shrna
    Targeting MUC1-C in human colon cancer cells downregulates LGR5, BMI1, and stemness. ( A ) Human SW620 colon cancer cells stably expressing a tet-CshRNA or <t>tet-MUC1shRNA</t> were treated with vehicle or 500 ng/mL DOX for 7 days. Lysates were immunoblotted with antibodies against the indicated proteins. ( B ) RNA-Seq was performed in triplicate on SW620 MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days. Silencing MUC1-C expression was significantly associated with suppression of the indicated HALLMARK gene sets. ( C ) SW620 cells were left untreated or treated with 5 μM GO-203 for 48 hours. Lysates were immunoblotted with antibodies against the indicated proteins. ( D ) SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 48 hours were monitored for wound healing in the scratch assay (left). The results are expressed as a percentage (mean ± SD of 3 biologic replicates) of the control at 0 hours (right). Scale bars: 100 μm. ( E ) SW620 cells left untreated or treated with 5 μM GO-203 for 48 hours were monitored for wound healing in the scratch assay (left). The results (mean ± SD of 3 biologic replicates) are expressed as a percentage of the control at 0 hours (right). Scale bars: 100 μm. ( F ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 24 hours were assayed for invasion (left). The results (mean ± SD of 3 biologic replicates) are expressed as the invasive cell number (right). Scale bar: 200 μm. ( G ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days were assayed for colony formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as colony number per field (right). ( H ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 5 days were assayed for tumorsphere formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as tumorsphere number per field (right). Scale bar: 200 μm.
    Inducible Gene Silencing Muc1shrna, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inducible gene silencing muc1shrna/product/Millipore
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    inducible gene silencing muc1shrna - by Bioz Stars, 2020-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    KD of EGR2 Reduces COL1A1 and PDGFRB mRNA Levels in Human HSC Line (A–C) Graphs show the effect of siRNA-KD of the indicated genes (x axis) on relative mRNA levels of EGR2 (A), COL1A1 (B), and PDGFRB (C). The effect of three independent siRNAs against EGR2 is shown. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA and Dunnett’s post test. Statistical differences are indicated as ***p

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing

    doi: 10.1016/j.omtn.2017.04.014

    Figure Lengend Snippet: KD of EGR2 Reduces COL1A1 and PDGFRB mRNA Levels in Human HSC Line (A–C) Graphs show the effect of siRNA-KD of the indicated genes (x axis) on relative mRNA levels of EGR2 (A), COL1A1 (B), and PDGFRB (C). The effect of three independent siRNAs against EGR2 is shown. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA and Dunnett’s post test. Statistical differences are indicated as ***p

    Article Snippet: siRNA Gene Silencing in Cell Lines The human HSC line LX-2 (EMD Millipore) was transfected with siRNAs against EGR2 , COL1A1 , or Luc with Lipofectamine RNAiMAX reagent following the manufacturer’s protocol.

    Techniques:

    Targeting MUC1-C in human colon cancer cells downregulates LGR5, BMI1, and stemness. ( A ) Human SW620 colon cancer cells stably expressing a tet-CshRNA or tet-MUC1shRNA were treated with vehicle or 500 ng/mL DOX for 7 days. Lysates were immunoblotted with antibodies against the indicated proteins. ( B ) RNA-Seq was performed in triplicate on SW620 MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days. Silencing MUC1-C expression was significantly associated with suppression of the indicated HALLMARK gene sets. ( C ) SW620 cells were left untreated or treated with 5 μM GO-203 for 48 hours. Lysates were immunoblotted with antibodies against the indicated proteins. ( D ) SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 48 hours were monitored for wound healing in the scratch assay (left). The results are expressed as a percentage (mean ± SD of 3 biologic replicates) of the control at 0 hours (right). Scale bars: 100 μm. ( E ) SW620 cells left untreated or treated with 5 μM GO-203 for 48 hours were monitored for wound healing in the scratch assay (left). The results (mean ± SD of 3 biologic replicates) are expressed as a percentage of the control at 0 hours (right). Scale bars: 100 μm. ( F ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 24 hours were assayed for invasion (left). The results (mean ± SD of 3 biologic replicates) are expressed as the invasive cell number (right). Scale bar: 200 μm. ( G ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days were assayed for colony formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as colony number per field (right). ( H ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 5 days were assayed for tumorsphere formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as tumorsphere number per field (right). Scale bar: 200 μm.

    Journal: JCI Insight

    Article Title: MUC1-C drives stemness in progression of colitis to colorectal cancer

    doi: 10.1172/jci.insight.137112

    Figure Lengend Snippet: Targeting MUC1-C in human colon cancer cells downregulates LGR5, BMI1, and stemness. ( A ) Human SW620 colon cancer cells stably expressing a tet-CshRNA or tet-MUC1shRNA were treated with vehicle or 500 ng/mL DOX for 7 days. Lysates were immunoblotted with antibodies against the indicated proteins. ( B ) RNA-Seq was performed in triplicate on SW620 MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days. Silencing MUC1-C expression was significantly associated with suppression of the indicated HALLMARK gene sets. ( C ) SW620 cells were left untreated or treated with 5 μM GO-203 for 48 hours. Lysates were immunoblotted with antibodies against the indicated proteins. ( D ) SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 48 hours were monitored for wound healing in the scratch assay (left). The results are expressed as a percentage (mean ± SD of 3 biologic replicates) of the control at 0 hours (right). Scale bars: 100 μm. ( E ) SW620 cells left untreated or treated with 5 μM GO-203 for 48 hours were monitored for wound healing in the scratch assay (left). The results (mean ± SD of 3 biologic replicates) are expressed as a percentage of the control at 0 hours (right). Scale bars: 100 μm. ( F ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 24 hours were assayed for invasion (left). The results (mean ± SD of 3 biologic replicates) are expressed as the invasive cell number (right). Scale bar: 200 μm. ( G ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days were assayed for colony formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as colony number per field (right). ( H ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 5 days were assayed for tumorsphere formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as tumorsphere number per field (right). Scale bar: 200 μm.

    Article Snippet: Inducible gene silencing.MUC1shRNA (MISSION shRNA TRCN0000122938), MYCshRNA (MISSION shRNA), or a control scrambled shRNA (CshRNA) (MilliporeSigma) was inserted into the pLKO-tet-puro vector (plasmid 21915; Addgene, Cambridge, Massachusetts, USA).

    Techniques: Stable Transfection, Expressing, RNA Sequencing Assay, Wound Healing Assay

    MUC1-C/MYC signaling induces LGR5 and BMI1 expression. ( A ). MUC1-C thereby forms a ternary complex with β-catenin and TCF4 on WNT target genes, such as CCND1 and MYC ). RNA-Seq was performed in triplicate on SW620 MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days. Silencing MUC1-C expression was significantly associated with suppression of the indicated HALLMARK gene set. ( B ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells were treated with vehicle or 500 ng/mL DOX for 7 days. ( C ) Nuclear lysates from SW620 cells were precipitated with anti–MUC1-C and an IgG control antibody. Input proteins and the precipitates were immunoblotted with antibodies against MUC1-C and MYC. ( D ) SW620 cells expressing a tet-MYCshRNA were treated with vehicle or 500 ng/mL DOX for 7 days. ( E ) Schema of the LGR5 promoter region. Soluble chromatin from SW620 cells was precipitated with a control IgG, anti–MUC1-C, or anti-MYC (left). Soluble chromatin was precipitated with anti–MUC1-C (ChIP) and then reprecipitated with anti-MYC or a control IgG (re-ChIP) (right). ( F ) Soluble chromatin from SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with 500 ng/mL DOX for 7 days was precipitated with anti-MYC or a control IgG. The DNA samples were amplified by quantitative PCR (qPCR) with primers for the LGR5 promoter. ( G ) Schema of the BMI1 ). Soluble chromatin from SW620 cells was precipitated with a control IgG, anti-MUC1-C or anti-MYC (left). Soluble chromatin was precipitated with anti-MUC1-C (ChIP) and then reprecipitated with anti-MYC or a control IgG (re-ChIP) (right). ( H ) Soluble chromatin from SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with 500 ng/mL DOX for 7 days was precipitated with anti-MYC or a control IgG. The DNA samples were amplified by qPCR with primers for the BMI1 promoter. The results (mean ± SD of 3 determinations) are expressed as the relative fold enrichment compared with that obtained with the IgG control (assigned a value of 1).

    Journal: JCI Insight

    Article Title: MUC1-C drives stemness in progression of colitis to colorectal cancer

    doi: 10.1172/jci.insight.137112

    Figure Lengend Snippet: MUC1-C/MYC signaling induces LGR5 and BMI1 expression. ( A ). MUC1-C thereby forms a ternary complex with β-catenin and TCF4 on WNT target genes, such as CCND1 and MYC ). RNA-Seq was performed in triplicate on SW620 MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days. Silencing MUC1-C expression was significantly associated with suppression of the indicated HALLMARK gene set. ( B ) SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells were treated with vehicle or 500 ng/mL DOX for 7 days. ( C ) Nuclear lysates from SW620 cells were precipitated with anti–MUC1-C and an IgG control antibody. Input proteins and the precipitates were immunoblotted with antibodies against MUC1-C and MYC. ( D ) SW620 cells expressing a tet-MYCshRNA were treated with vehicle or 500 ng/mL DOX for 7 days. ( E ) Schema of the LGR5 promoter region. Soluble chromatin from SW620 cells was precipitated with a control IgG, anti–MUC1-C, or anti-MYC (left). Soluble chromatin was precipitated with anti–MUC1-C (ChIP) and then reprecipitated with anti-MYC or a control IgG (re-ChIP) (right). ( F ) Soluble chromatin from SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with 500 ng/mL DOX for 7 days was precipitated with anti-MYC or a control IgG. The DNA samples were amplified by quantitative PCR (qPCR) with primers for the LGR5 promoter. ( G ) Schema of the BMI1 ). Soluble chromatin from SW620 cells was precipitated with a control IgG, anti-MUC1-C or anti-MYC (left). Soluble chromatin was precipitated with anti-MUC1-C (ChIP) and then reprecipitated with anti-MYC or a control IgG (re-ChIP) (right). ( H ) Soluble chromatin from SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with 500 ng/mL DOX for 7 days was precipitated with anti-MYC or a control IgG. The DNA samples were amplified by qPCR with primers for the BMI1 promoter. The results (mean ± SD of 3 determinations) are expressed as the relative fold enrichment compared with that obtained with the IgG control (assigned a value of 1).

    Article Snippet: Inducible gene silencing.MUC1shRNA (MISSION shRNA TRCN0000122938), MYCshRNA (MISSION shRNA), or a control scrambled shRNA (CshRNA) (MilliporeSigma) was inserted into the pLKO-tet-puro vector (plasmid 21915; Addgene, Cambridge, Massachusetts, USA).

    Techniques: Expressing, RNA Sequencing Assay, Chromatin Immunoprecipitation, Amplification, Real-time Polymerase Chain Reaction